Advertisement

The Current Landscape of PARP Inhibitors in Ovarian Cancer

  • Camille C. Gunderson
  • Britt K. Erickson
  • Megan E. Buechel
  • Kathleen N. Moore
Gynecologic Oncology (A Fader, Section Editor)
  • 129 Downloads
Part of the following topical collections:
  1. Topical Collection on Gynecologic Oncology

Abstract

Purpose of Review

The aim of this study is to discuss the background of PARP inhibitors and to provide an overview of the utility of these drugs for treatment of epithelial ovarian cancer.

Recent Findings

Numerous phase I–III trials are presented within the manuscript that outline the safety and efficacy of several PARP inhibitors in women with primary and recurrent ovarian cancer. There are now three FDA-approved PARP inhibitors for use in ovarian cancer patients in the USA: olaparib, niraparib, and rucaparib. These drugs have activity both alone and in combination with other agents, including chemotherapy and targeted anti-cancer drugs. Although PARP inhibitor toxicities often overlap with chemotherapy including myelosuppression, fatigue, and gastrointestinal distress, there are idiosyncratic differences in adverse event profiles and peculiar aspects of each drug. Additionally, the indications for use differ with respect to line of chemotherapy, whether a germline or somatic BRCA mutation is required, and maintenance versus active treatment intention. Although these were initially thought to be only applicable to patients with germline BRCA mutations, we now know that other patients benefit from these agents alone and in combination.

Summary

The first PARP inhibitor was approved for use in the USA less than 3 years ago, but we are rapidly gaining knowledge about when and in which settings to use these drugs. Continued focused study with clinical trials will enable us to identify the optimal patient populations for prescription of these agents.

Keywords

PARP inhibitors Ovarian cancer Epithelial ovarian cancer Olaparib Niraparib Rucaparib 

Notes

Compliance with Ethical Standards

Conflict of Interest

Britt K. Erickson and Megan E. Buechel declare no conflict of interest. Camille C. Gunderson is on the Clovis advisory board Dr Gunderson is also a consultant for Celsion. Kathleen N. Moore is on the advisory boards for Genentech Roche, Astra Zeneca, Amgen, Immunogen, Clovis, Tesaro, Janssen, and VBL Therapeutics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.  https://doi.org/10.1038/nature03445.CrossRefPubMedGoogle Scholar
  2. 2.
    Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010;39(1):8–24.  https://doi.org/10.1016/j.molcel.2010.06.017.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99.  https://doi.org/10.1158/0008-5472.CAN-12-2753.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17.  https://doi.org/10.1126/scitranslmed.aaf9246.CrossRefPubMedGoogle Scholar
  5. 5.
    Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–61.  https://doi.org/10.1158/1078-0432.CCR-15-0887.CrossRefPubMedGoogle Scholar
  6. 6.
  7. 7.
    •• Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64. This phase 3 trial, NOVA, provided provocative data which precipitated the approval of niraparib in recurrent ovarian cancer patients with and without BRCA mutations.CrossRefPubMedGoogle Scholar
  8. 8.
    Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-61.Google Scholar
  9. 9.
    •• Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50. This basket trial of olaparib in patients with a germline BRCA mutation led to the approval of olaparib in 2014, the first FDA approved PARP inhibitor in the United States.CrossRefPubMedGoogle Scholar
  10. 10.
    Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017.Google Scholar
  11. 11.
    •• Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87. This phase 2 trial led to the approval of rucaparib in 2016 in patients with germline or somatic BRCA mutations and recurrent ovarian cancer.CrossRefPubMedGoogle Scholar
  12. 12.
    Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016;27(6):1013–9.  https://doi.org/10.1093/annonc/mdw133.CrossRefPubMedGoogle Scholar
  13. 13.
    Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882–92.  https://doi.org/10.1016/S1470-2045(13)70240-7.CrossRefPubMedGoogle Scholar
  14. 14.
    Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation—an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;137(3):386–91.  https://doi.org/10.1016/j.ygyno.2015.03.042.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA repair. 2015;32:180–9.  https://doi.org/10.1016/j.dnarep.2015.04.030.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Joyce F. Liu WTB, Michael J. Birrer, J-ML, Buckanovich RJ, Fleming GF et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. ASCO 20172017.Google Scholar
  17. 17.
    Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14.  https://doi.org/10.1016/S1470-2045(14)70391-2.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3(1):11.  https://doi.org/10.1186/s40661-016-0033-6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257–68.  https://doi.org/10.1158/2326-6066.CIR-15-0044.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sarah Foster Adams OR, Lee J-H, McCance DJ, Westgate S, Eberhardt SC, Rutledge T, Muller C. Phase I study combining olaparib and tremelimumab for the treatment of women with BRCA-deficient recurrent ovarian cancer. ASCO 20172017.Google Scholar
  21. 21.
    Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in women's cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35(19):2193–202.  https://doi.org/10.1200/JCO.2016.72.1340.CrossRefPubMedGoogle Scholar
  22. 22.
    Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28(3):512–8.  https://doi.org/10.1093/annonc/mdw672.PubMedGoogle Scholar
  23. 23.
    Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21(13):2460–5.  https://doi.org/10.1200/JCO.2003.07.013.CrossRefPubMedGoogle Scholar
  24. 24.
    du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–82.  https://doi.org/10.1200/JCO.2014.55.7348.CrossRefPubMedGoogle Scholar
  25. 25.
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.  https://doi.org/10.1056/NEJMoa1104390.CrossRefPubMedGoogle Scholar
  26. 26.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.  https://doi.org/10.1056/NEJMoa1103799.CrossRefPubMedGoogle Scholar
  27. 27.
    Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.  https://doi.org/10.1056/NEJMoa1105535.CrossRefPubMedGoogle Scholar
  28. 28.
    Pujade-Lauraine E, Ledermann J, Penson R, et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the Phase III SOLO2 Study. Presented at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO), March 12–15. National Harbor, Maryland. 2017.Google Scholar
  29. 29.
    Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203.  https://doi.org/10.1016/j.ygyno.2015.12.020.CrossRefPubMedGoogle Scholar
  30. 30.
    Pujade-Laurainea JAL, Pensonc RT, Ozad AM, Korache J, Huzarskif T, Povedag A, Pignatah S, Friedlanderiand M, Colomboj N, editor. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study Society of Gynecologic Oncology Annual Meeting; 2017 03/14/2017; National Harbor, MD.Google Scholar
  31. 31.
    D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010;362(20):1909–19.  https://doi.org/10.1056/NEJMra0809889.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, et al. Successes and challenges of PARP inhibitors in cancer therapy. Front Oncol. 2015;5:222.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    FDA. Summary Review for Regulatory Action. 2014.Google Scholar
  34. 34.
    Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20(3):540–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2013;229(3):422–9.  https://doi.org/10.1002/path.4140.CrossRefPubMedGoogle Scholar
  36. 36.
    Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116–20.  https://doi.org/10.1038/nature06633.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008;68(8):2581–6.  https://doi.org/10.1158/0008-5472.CAN-08-0088.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35(12):1274–80.  https://doi.org/10.1200/JCO.2016.70.4627.CrossRefPubMedGoogle Scholar
  39. 39.
    Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Przeglad Menopauzalny Menopause Rev. 2016;15(4):215–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Camille C. Gunderson
    • 1
  • Britt K. Erickson
    • 2
  • Megan E. Buechel
    • 1
  • Kathleen N. Moore
    • 1
  1. 1.Stephenson Cancer Center, Section of Gynecologic OncologyThe University of OklahomaOklahoma CityUSA
  2. 2.Department of Obstetrics and Gynecology, Division of Gynecologic OncologyUniversity of MinnesotaMinneapolisUSA

Personalised recommendations